News

Vertex to Acquire ViaCyte for $320 Million

July 18, 2022

Vertex’s $320 million acquisition of ViaCyte will give the company complementary capabilities for its Type 1 diabetes therapy program.

FDA Regulation of Nonprescription Drugs in Spotlight

July 14, 2022

Application for OTC contraceptive highlights efforts to broaden access to medicines.

WHO’s Science Council Calls for Equitable Expansion of Genomics

July 13, 2022

WHO’s Science Council released a report calling for a collective effort to accelerate global access to genomics.

Merck Digital Sciences Studio Supports Early-Stage Startups

July 13, 2022

Merck, known as MSD outside the United States and Canada, now offers the Merck Digital Sciences Studio, designed to enable innovative tech for drug discovery and development.

Pfizer and Touchlight Enter Patent License Agreement for Use of dbDNA

July 13, 2022

Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.

Wacker Biotech Expands Germany Site with Construction of New mRNA Competence Center

July 12, 2022

Wacker is investing more than €100 million (US$100.5 million) to expand its Halle, Germany, site with an mRNA competence center.

Coya Therapeutics Secures Rights to Exosome Engineering Technology from Carnegie Mellon University

July 08, 2022

Coya Therapeutics has secured intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids.

Bio-Rad Launches CFX Opus Deepwell Real-Time PCR Detection System

July 08, 2022

Bio-Rad’s CFX Opus Deepwell Real-Time PCR Detection System is designed to support researchers in developing nucleic acid detection assays.

Bio-Rad Launches New Chromatography Column Packs

July 08, 2022

Bio-Rad’s EconoFit Chromatography Column Packs support resin screening experiments in the development of protein purification workflows.

FDA Drug Regulation Challenged by Anti-Abortion Campaign

July 08, 2022

Some states look to block access to approved drugs.